The page below is a sample from the LabCE course Multi-drug Resistant Organisms: MRSA, VRE, and Clostridium difficile. Access the complete course and earn ASCLS P.A.C.E.-approved continuing education credits by subscribing online.

Learn more about Multi-drug Resistant Organisms: MRSA, VRE, and Clostridium difficile (online CE course) »
How to Subscribe
MLS & MLT Comprehensive CE Package
Includes 97 CE courses, most popular
$95 Add to cart
Pick Your Courses
Up to 8 CE hours
$50 Add to cart
Individual course$20 Add to cart

Future Perspectives

With MRSA becoming the "new normal" in many areas, clinicians will have to define the role of up to a dozen anti-MRSA drugs. Alternatives to vancomycin include older drugs like clindamycin, doxycycline, and trimethoprim/sulfamethoxazole, and newer agents like linezolid and daptomycin for serious infections. There are also a number of drugs under development including enhanced glycopeptides – dalbavancin, oritavancin, telavancin, and anti-MRSA cephalosporins.